原始来源记录
决策级顶线结果
Verastem：RAMP 301 3期顶线数据预计于2027年年中公布
2026年3月企业演示文稿指出，RAMP 301确证性3期试验（avutometinib + defactinib对比研究者选择疗法，用于复发性LGSOC）将于2027年年中公布顶线数据。该数据旨在确认RAMP 201结果，并可能扩大AVMAPKI FAKZYNJA CO-PACK的获批适应症，无论KRAS突变状态如何。
关键事实
- 申报时间
- 2026年3月4日 21:15
- 事件
- 顶线结果
- 方向
- 中性
- 来源
- SEC 8-K
- 可信度
- 有来源
来源摘录
EX-99.1 2 tm267866d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway-Driven Cancers C O R P O R A T E P R E S E N T A T I O N M A R C H 2 0 2 6 2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC), the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc